Opiant Pharmaceuticals, Inc. Common Stock
OPNT
OPNT was delisted on the 1st of March, 2023.
23 hedge funds and large institutions have $11.1M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 8 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
5% less capital invested
Capital invested by funds: $11.7M → $11.1M (-$543K)
12% less funds holding
Funds holding: 26 → 23 (-3)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.81M |
| 2 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$814K |
| 3 |
PCM
Prelude Capital Management
New York
|
+$395K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$287K |
| 5 |
EP
Eversept Partners
New York
|
+$227K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HI
HBK Investments
Dallas,
Texas
|
-$1.07M |
| 2 |
CLCM
Crawford Lake Capital Management
Lakewood,
New Jersey
|
-$841K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$781K |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$245K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$90.1K |
OPNT Hedge Fund Activity: Q4 2018 in Review
23 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q4 2018, worth a combined $11.1M — down 4.7% from $11.7M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of OPNT and 5 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 8 added.
The largest buyer was Stonepine Capital Management, adding an estimated $2.81M. The largest seller was HBK Investments, exiting entirely with an estimated $1.07M sold.
- 23 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q4 2018, down from 26 in Q3 2018.
- Funds reported $11.1M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q4 2018, down 4.7% quarter-over-quarter.
- 5 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q4 2018 and 8 closed out, a net change of -3 holders.
- The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q4 2018 was Stonepine Capital Management, an estimated $2.81M added.
- The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q4 2018 was HBK Investments, an estimated $1.07M sold.
Based on aggregated 13F filings for Q4 2018.